Journal article icon

Journal article

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes

Abstract:

PURPOSE
Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion–dependent anemia and thrombocytopenia.
METHODS
Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end poi... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1200/jco.20.02619

Authors


More by this author
Role:
Author
ORCID:
0000-0002-3631-2482
More by this author
Role:
Author
ORCID:
0000-0002-5439-2172
Publisher:
American Society of Clinical Oncology
Journal:
Journal of Clinical Oncology More from this journal
Volume:
39
Issue:
13
Pages:
1426-1436
Publication date:
2021-03-25
Acceptance date:
2021-02-07
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Pmid:
33764805

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP